Laura Harvey1, Christopher T Holley1, Ranjit John1. 1. 1 Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA ; 2 Division of Cardiovascular and Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.
Abstract
BACKGROUND: Continuous-flow left ventricular assist devices (CF-LVADs) have become the standard of care for patients with end-stage heart failure (HF). While these devices have improved durability compared to earlier generation left ventricular assist devices (LVADs), increased frequency in some complications has been seen, including gastrointestinal bleeding (GIB), pump thrombosis and hemolysis. We discuss the incidence, management and prevention of GIB after CF-LVAD implantation. METHODS: We reviewed the current literature available on the incidence, management and prevention of GIB after CF-LVAD implantation with a focus on our experience at the University of Minnesota, with data on nearly 300 patients who received a CF-LVAD from 2005 to 2013. RESULTS: The incidence of GIB after CF-LVAD varies between 18-40% in numerous studies. At the University of Minnesota, out of 233 patients who underwent HeartMate II (HMII) implantation between 2005-2013, 60 GIB episodes occurred in 51 patients (22%), with an event rate of 0.17 gastrointestinal bleeds/patient-year of support. The etiology of GIB appears to be multifactorial. The main factors which have been identified include the need for chronic anticoagulation, acquired von Willebrand syndrome, platelet dysfunction and increased incidence of arteriovenous malformations due to chronic low pulse pressure. When managing an LVAD patient with GIB, a multi-disciplinary approach is needed. The main goals of treatment are evaluating the location and severity of the bleed, holding anti-coagulants and resuscitation to maintain stable hemodynamics. CONCLUSIONS: GIB is a complication with considerable morbidity. Future efforts to further understand the etiology of GIB and optimize anti-coagulation are needed to improve outcomes following CF-LVAD implantation.
BACKGROUND: Continuous-flow left ventricular assist devices (CF-LVADs) have become the standard of care for patients with end-stage heart failure (HF). While these devices have improved durability compared to earlier generation left ventricular assist devices (LVADs), increased frequency in some complications has been seen, including gastrointestinal bleeding (GIB), pump thrombosis and hemolysis. We discuss the incidence, management and prevention of GIB after CF-LVAD implantation. METHODS: We reviewed the current literature available on the incidence, management and prevention of GIB after CF-LVAD implantation with a focus on our experience at the University of Minnesota, with data on nearly 300 patients who received a CF-LVAD from 2005 to 2013. RESULTS: The incidence of GIB after CF-LVAD varies between 18-40% in numerous studies. At the University of Minnesota, out of 233 patients who underwent HeartMate II (HMII) implantation between 2005-2013, 60 GIB episodes occurred in 51 patients (22%), with an event rate of 0.17 gastrointestinal bleeds/patient-year of support. The etiology of GIB appears to be multifactorial. The main factors which have been identified include the need for chronic anticoagulation, acquired von Willebrand syndrome, platelet dysfunction and increased incidence of arteriovenous malformations due to chronic low pulse pressure. When managing an LVAD patient with GIB, a multi-disciplinary approach is needed. The main goals of treatment are evaluating the location and severity of the bleed, holding anti-coagulants and resuscitation to maintain stable hemodynamics. CONCLUSIONS: GIB is a complication with considerable morbidity. Future efforts to further understand the etiology of GIB and optimize anti-coagulation are needed to improve outcomes following CF-LVAD implantation.
Authors: Jeffrey A Morgan; Gaetano Paone; Hassan W Nemeh; Scott E Henry; Rosan Patel; Jessica Vavra; Celeste T Williams; David E Lanfear; Cristina Tita; Robert J Brewer Journal: J Heart Lung Transplant Date: 2012-03-14 Impact factor: 10.247
Authors: Vladimir M Kushnir; Shivak Sharma; Gregory A Ewald; Jonathan Seccombe; Eric Novak; I-Wen Wang; Susan M Joseph; C Prakash Gyawali Journal: Gastrointest Endosc Date: 2012-02-15 Impact factor: 9.427
Authors: Jolanta Klovaite; Finn Gustafsson; Svend A Mortensen; Kåre Sander; Lars B Nielsen Journal: J Am Coll Cardiol Date: 2009-06-09 Impact factor: 24.094
Authors: O H Frazier; M P Macris; T J Myers; J M Duncan; B Radovancević; S M Parnis; D A Cooley Journal: Ann Thorac Surg Date: 1994-06 Impact factor: 4.330
Authors: Nandan K Mondal; Zengsheng Chen; Jaimin R Trivedi; Erik N Sorensen; Si M Pham; Mark S Slaughter; Bartley P Griffith; Zhongjun J Wu Journal: ASAIO J Date: 2018 Jul/Aug Impact factor: 2.872
Authors: Nandan K Mondal; Michael A Sobieski; Si M Pham; Bartley P Griffith; Steven C Koenig; Mark S Slaughter; Zhongjun J Wu Journal: ASAIO J Date: 2017 Mar/Apr Impact factor: 2.872
Authors: Nandan K Mondal; Tieluo Li; Zengsheng Chen; Hegang H Chen; Erik N Sorensen; Si M Pham; Michael A Sobieski; Steven C Koenig; Mark S Slaughter; Bartley P Griffith; Zhongjun J Wu Journal: Mol Cell Biochem Date: 2017-03-25 Impact factor: 3.396
Authors: Christopher R Tainter; Oscar Ö Braun; Felipe Teran; Albert P Nguyen; Kimberly Robbins; Edward O O'Brien; Zeb M McMillan; Ulrich Schmidt; Angela Meier; Mat Goebel; Victor Pretorius; Michela Brambatti; Eric D Adler; Raghu Seethala Journal: Intern Emerg Med Date: 2017-12-22 Impact factor: 3.397
Authors: Nandan K Mondal; Zengsheng Chen; Jaimin R Trivedi; Erik N Sorensen; Si M Pham; Mark S Slaughter; Bartley P Griffith; Zhongjun J Wu Journal: Thromb Res Date: 2017-09-08 Impact factor: 3.944
Authors: Raymond V Mirasol; Jason J Tholany; Hasini Reddy; Billie S Fyfe-Kirschner; Christina L Cheng; Issam F Moubarak; John L Nosher Journal: World J Radiol Date: 2016-04-28